PharmaShots Interview: In Conversation with Portage’s CEO and Director, Dr. Ian Walters, Where he Shares Insights on Ongoing Clinical-Stage and Development Programs

Shots:Ian spoke about the study design of the clinical trials of its lead iNKT agonistsHe also emphasized the advancement of novel immunotherapies through new collaborations The interview provides a gist of Portage's development plan for its pipeline and various options to improve cancer treatmentSmriti: Explain the details (MOA, ROA, formulations, etc.) of PORT-2 & PORT-3?…